Episode Summary
Executive Summary: The episode explores brain-computer interfaces (BCIs) with Paradromics CEO Matt Engel, focusing on high-data-rate neural recording, speech restoration, and future applications for paralysis, pain, and mental health. Engel argues that BCIs will first provide practical medical benefits—especially communication and objective brain-state measurement—before expanding into visual and auditory prosthetics and immersive AR/VR.
Main Topics: Paradromics and the BCI platform: Engel explains Paradromics’ mission to build a clinically viable, high-bandwidth brain-computer interface that records neural activity at the level of individual neurons and translates it into actionable digital output. From basic neuroscience to medical devices: He describes how his academic work on electrodes, single-cell recording, and scalable neural interfaces led him to focus on clinical translation for disability treatment rather than basic science alone. Speech decoding and restoration of communication: A major near-term use case is helping people who cannot speak by decoding intended speech from cortical activity and turning it into text and synthesized voice in the patient’s own voice. Paralysis, prosthetics, and embodied control: The discussion contrasts long-term biological cures for paralysis with near-term neural engineering solutions like wheelchairs, robotic limbs, and exoskeletons controlled directly by the brain. Pain, mental health, and objective brain-state measurement: Engel argues BCIs could provide real-time measures of pain, mood, and cognitive state, improving treatment selection for chronic pain, depression, PTSD, and related conditions. Ethics, regulation, and commercialization: The conversation covers FDA oversight, reimbursement, device abandonment, and the tension between medical benefit and more speculative augmentation or subscription-based models. Long-term sci-fi implications: Shermer and Engel discuss consciousness, free will, animal cognition, mind uploading, and future visual prostheses that could enable AR/VR indistinguishable from natural vision.
Key Arguments: High-data-rate BCIs are the bottleneck: medical and consumer applications depend on getting more information in and out of the brain, faster and more precisely. Neural engineering can deliver benefits now, even if biological cures for paralysis or spinal cord injury remain decades away. Speech decoding from neural activity is already viable and can restore communication to people with severe motor speech loss. Objective brain-state readouts could replace crude self-report scales for pain and mood, improving psychiatric and pain treatment. What appears “less invasive” is not always less invasive; long-term opiate use may be more harmful than a brain implant or DBS. BCIs will likely evolve like semiconductor and internet technologies: better hardware and bandwidth will unlock entirely new applications. The field’s long-term value may come from aligning cutting-edge augmentation goals with major medical needs such as blindness, deafness, and paralysis.
Data Points: One cortical module transfer rate: 200 bits per second - Engel says Paradromics’ system achieved this in sheep testing, described as the highest data rate BCI in the world. Relative speed vs. Neuralink: About 20x faster - Engel claims Paradromics’ tested transfer rate is roughly twenty times faster than Neuralink. Implant diameter: About 10 millimeters - He describes the size of the implant that sits on the brain surface. Electrode depth: About 1.5 millimeters - The implant’s hair-like electrodes insert into cortical tissue to record neural activity. Company founding year: 2015 - Paradromics was started during the Obama Brain Initiative era. NIH grant: $800,000 - The company initially formed to accept an NIH grant. DoD funding year: 2017 - Paradromics won a competitive Department of Defense contract in 2017. Company headcount: 75 - Engel says Paradromics has about 75 employees. First device development cost: $120 million - Engel says Paradromics spent this amount developing its first device. Neuralink device development spend: $500-$600 million - He compares Paradromics’ spend to Neuralink’s higher development cost. Commercial approval target: 2030 - Paradromics is aiming for commercial approval around 2030. Clinical trial timing: Q1 of next year / early 2026 - He says the first clinical trial is planned for early 2026 pending regulatory approval. Human first recording: May 2025 - Shermer notes Paradromics performed its first in-human neural recording in May 2025.
Pivotal Quotes: "one of our cortical modules can transfer 200 bits per second, which is the highest data rate brain computer interface in the world" — Matt Engel: He is describing Paradromics’ sheep testing results and claiming a speed advantage over competitors. "People often have a, their intuition for what is invasive and what is not invasive in medicine can be wrong." — Matt Engel: He argues that brain implants can be less invasive in practice than prolonged opioid treatment. "When vision restoration reaches 2020 vision, then a BCI-provided image will be indistinguishable from one that was delivered by the eye." — Matt Engel: He outlines the long-term promise of visual prosthetics and immersive AR/VR.
Implications: BCIs are moving from speculative neuroscience toward real clinical tools, first for speech and disability, then pain and mental health. If bandwidth, safety, and reimbursement scale, the field could redefine neurorehabilitation and human-computer interaction.